Details of the Drug Combinations

General Information of This Drug (ID: DMQMBZ1)

• Drug Name: Rivaroxaban (DMQMBZ1)
• Synonyms: XARELTO (TN)

Indication

Deep vein thrombosis; ICD 11: BD71; Status: Approved [1]; Heparin-induced thrombocytopenia; ICD 11: 3B64.12; Status: Approved [2]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 3 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rivaroxaban + Idarubicin	DCP2O5G	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]

14 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rivaroxaban + Rivaroxaban	DCGSO65	Rivaroxaban	Atrial Fibrillation	[5]
Apixaban + Rivaroxaban	DCMI6XF	Apixaban	Cancer-associated Thrombosis	[6]
Brilinta + Rivaroxaban	DCWW9VB	Brilinta	Acute Coronary Syndrome	[7]
Clopidogrel + Rivaroxaban	DC3DY4X	Clopidogrel	Acute Coronary Syndrome	[7]
Warfarin + Rivaroxaban	DCD86UT	Warfarin	Valvular Heart Disease	[8]
Apixaban + Rivaroxaban	DCFC0H9	Apixaban	Renal Insufficiency	[9]
Aspirin + Rivaroxaban	DCDSKNN	Aspirin	Transcatheter Aortic Valve Replacement	[10]
Aspirin + Rivaroxaban	DCS32O9	Aspirin	Aortic Valve Stenosis	[11]
Brilinta + Rivaroxaban	DC5WOHZ	Brilinta	Atrial Fibrillation	[12]
Aspirin + Rivaroxaban	DCBOPA1	Aspirin	Coronary Artery Disease	[13]
Clopidogrel + Rivaroxaban	DC2I0J8	Clopidogrel	Atrial Fibrillation	[14]
Diosmin + Rivaroxaban	DCKQAM0	Diosmin	Deep Vein Thrombosis	[15]
Doxycycline + Rivaroxaban	DCT8K3K	Doxycycline	COVID-19	[16]
Tranexamic acid + Rivaroxaban	DCYXVLP	Tranexamic acid	Osteoarthritis, Knee	[17]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388).
• [2] Rivaroxaban FDA Label
• [3] Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] ClinicalTrials.gov (NCT05960721) Low-dose NOAC Versus GDMT After LAAO
• [6] ClinicalTrials.gov (NCT03139487) A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
• [7] ClinicalTrials.gov (NCT02293395) A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
• [8] ClinicalTrials.gov (NCT02303795) RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial
• [9] ClinicalTrials.gov (NCT02664155) Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
• [10] ClinicalTrials.gov (NCT02556203) Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
• [11] ClinicalTrials.gov (NCT02833948) Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
• [12] ClinicalTrials.gov (NCT03331484) The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
• [13] ClinicalTrials.gov (NCT04006288) Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
• [14] ClinicalTrials.gov (NCT04023630) DUAL Antithrombotic Therapy in Patients With AF and ACS
• [15] ClinicalTrials.gov (NCT03413618) Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
• [16] ClinicalTrials.gov (NCT04715295) Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
• [17] ClinicalTrials.gov (NCT03328832) Combined Topical Tranexamic Acid With Floseal in Total Knee Arthroplasty